AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

Tencent Music Entertainment Group

$7.93 -$9.93 (-55.57%)
NYSE · 15 Sep 2026 18:23 UTC
Previous Close
$8.11
Day Range
$7.88$8.11
Year Range
$7.77$26.7
Market Cap
12.2B
AVG Volume
10.01M
Trailing/Forward PE
9.47/1.24
PEG ratio
1.22
Dividend Yield
2.97%
Next Earnings Date
2026-11-11
Primary Exchange
New York Stock ExchangeUS
Revenue (CNY)
02.5B5B7.5B10B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TME Revenue (CNY) by quarter
PeriodRevenue (CNY)
26 Q28.93B
26 Q17.85B
25 Q47.74B
25 Q38.46B
25 Q28.44B
25 Q17.36B
24 Q47.46B
24 Q37.01B
24 Q27.16B
24 Q16.77B
Net Income (CNY)
02B4B6B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TME Net Income (CNY) by quarter
PeriodNet Income (CNY)
26 Q22.47B
26 Q12.08B
25 Q41.9B
25 Q32.15B
25 Q22.41B
25 Q14.29B
24 Q41.96B
24 Q31.58B
24 Q21.68B
24 Q11.42B
Operating Income (CNY)
02B4B6B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TME Operating Income (CNY) by quarter
PeriodOperating Income (CNY)
26 Q23.04B
26 Q12.32B
25 Q42.62B
25 Q32.71B
25 Q22.98B
25 Q14.84B
24 Q42.41B
24 Q32.14B
24 Q22.2B
24 Q11.96B
EBITDA (CNY)
02B4B6B8B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TME EBITDA (CNY) by quarter
PeriodEBITDA (CNY)
26 Q23.14B
26 Q12.71B
25 Q46.36B
25 Q32.64B
25 Q23.17B
25 Q12.35B
24 Q42.33B
24 Q32.02B
24 Q22.07B
24 Q11.86B
Cash Flows (CNY)
01B2B3B4B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TME Cash Flows (CNY) by quarter
PeriodCash Flows (CNY)
26 Q22.86B
26 Q12.33B
25 Q40
25 Q33.68B
25 Q21.64B
25 Q12.52B
24 Q42.16B
24 Q32.17B
24 Q22.94B
24 Q12.69B
EPS (CNY)
012324 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TME EPS (CNY) by quarter
PeriodEPS (CNY)
26 Q21.58
26 Q11.34
25 Q41.2
25 Q31.38
25 Q21.56
25 Q12.78
24 Q41.26
24 Q31
24 Q21.08
24 Q10.92
Expenses (CNY)
-2B02B4BR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TME Expenses (CNY) by quarter
PeriodExpenses (CNY)
26 Q21.29B
26 Q11.21B
25 Q41.27B
25 Q31.31B
25 Q21.16B
25 Q11.14B
24 Q43.77B
24 Q31.22B
24 Q21.15B
24 Q11.14B
Cash & Debt (CNY)
010B20B30B40BCashLong Term DebtShort Term Debt24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TME Cash & Debt (CNY) by quarter
PeriodCash & Debt (CNY)
26 Q230.65B
26 Q126.66B
25 Q424.35B
25 Q322.32B
25 Q222.2B
25 Q126.69B
24 Q427.21B
24 Q328.56B
24 Q224.55B
24 Q126.62B
Debt ratios
-4-3-2-1024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TME Debt ratios by quarter
PeriodDebt ratios
26 Q2-0.93
26 Q1-1.47
25 Q4-1.41
25 Q3-1.76
25 Q2-1.64
25 Q1-2.35
24 Q4-2.55
24 Q3-3.39
24 Q2-3.07
24 Q1-3.78
Margins
0%25%50%75%100%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TME Margins by quarter
PeriodMargins
26 Q244.21%
26 Q144.91%
25 Q497.73%
25 Q343.51%
25 Q244.41%
25 Q144.07%
24 Q443.62%
24 Q342.64%
24 Q242.04%
24 Q140.94%
Return on Capital
0%2%4%6%24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TME Return on Capital by quarter
PeriodReturn on Capital
26 Q23.05%
26 Q12.7%
25 Q42.29%
25 Q32.52%
25 Q22.79%
25 Q15.71%
24 Q42.81%
24 Q32.43%
24 Q22.67%
24 Q12.34%
Shares Outstanding
0500M1B1.5B2B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TME Shares Outstanding by quarter
PeriodShares Outstanding
26 Q21.54B
26 Q11.54B
25 Q41.53B
25 Q31.56B
25 Q21.53B
25 Q11.53B
24 Q41.55B
24 Q31.57B
24 Q21.54B
24 Q11.54B
Dividends (CNY)
00.10.20.3May 24Apr 25Apr 26
TME Dividends (CNY) by quarter
PeriodDividends (CNY)
Apr 260.24
Apr 250.18
May 240.14
Employee Count
02K4K6K20212022202320242025
TME Employee Count by quarter
PeriodEmployee Count
20255.69K
20245.35K
20235.18K
20225.8K
20215.97K
Book Value Per Share (CNY)
020406024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TME Book Value Per Share (CNY) by quarter
PeriodBook Value Per Share (CNY)
26 Q252.62
26 Q149.88
25 Q454.19
25 Q354.79
25 Q256.46
25 Q149.24
24 Q444.89
24 Q341.62
24 Q240.73
24 Q139.43
Total Assets (CNY)
050B100B150B24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
TME Total Assets (CNY) by quarter
PeriodTotal Assets (CNY)
26 Q2116.95B
26 Q199.48B
25 Q4102.59B
25 Q3104.87B
25 Q2107.87B
25 Q198.08B
24 Q490.44B
24 Q384.61B
24 Q282.41B
24 Q179.18B
PE Ratio
51015202530med 20.69Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
TME PE Ratio by quarter
PeriodPE Ratio
Sep 269.74
Sep 269.58
Sep 269.93
Aug 2610.38
Aug 2610.67
Aug 2610.75
Aug 2611.6
Jul 2611.51
Jul 2610.82
Jul 2611.14
Jul 2610.85
Jul 2610.57
Jun 2610.29
Jun 2610.66
Jun 2611.24
Jun 2611.08
May 2611.25
May 2610.8
May 2610.4
May 268.96
May 268.86
Apr 269.1
Apr 269.8
Apr 269.11
Apr 269
Mar 269.29
Mar 269.91
Mar 2614.11
Mar 2613.55
Feb 2614.44
Feb 2615.14
Feb 2615.79
Feb 2616.35
Jan 2616.82
Jan 2616.87
Jan 2616.66
Jan 2617.46
Jan 2618.01
Dec 2517.81
Dec 2518.07
Dec 2518.54
Dec 2518.95
Nov 2518.83
Nov 2518.6
Nov 2519.38
Nov 2522.64
Oct 2523.73
Oct 2524.36
Oct 2523.81
Oct 2523.91
Oct 2524.35
Sep 2525.18
Sep 2526.69
Sep 2526.61
Sep 2526.1
Aug 2526.12
Aug 2527.14
Aug 2527.41
Aug 2525.52
Aug 2523.78
Jul 2524.51
Jul 2524.69
Jul 2522.77
Jul 2522.39
Jun 2521.99
Jun 2521.24
Jun 2521.23
Jun 2520.73
May 2519.46
May 2520.19
May 2519.23
May 2523.82
May 2524.32
Apr 2522.76
Apr 2523.46
Apr 2523.32
Apr 2524.68
Mar 2527.31
Mar 2526.54
Mar 2523.75
Mar 2525.2
Feb 2523.22
Feb 2527.27
Feb 2525.82
Feb 2523.9
Jan 2522.72
Jan 2521.96
Jan 2520.65
Jan 2520.59
Jan 2521.36
Dec 2422.37
Dec 2422.8
Dec 2422.79
Dec 2423.86
Nov 2421.61
Nov 2423.12
Nov 2422.15
Nov 2422.63
Nov 2421.92
Oct 2422.64
Free Cash Flow Yield
2%4%6%8%10%12%med 6.53%Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
TME Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 2610.59%
Sep 2610.77%
Sep 2610.4%
Aug 268.63%
Aug 268.4%
Aug 268.34%
Aug 267.73%
Jul 267.79%
Jul 268.28%
Jul 268.04%
Jul 268.26%
Jul 268.48%
Jun 268.71%
Jun 268.41%
Jun 267.97%
Jun 268.09%
May 267.96%
May 268.3%
May 268.61%
May 268.14%
May 268.23%
Apr 268.01%
Apr 267.44%
Apr 268%
Apr 268.1%
Mar 267.84%
Mar 267.36%
Mar 266.56%
Mar 266.83%
Feb 266.41%
Feb 266.11%
Feb 265.86%
Feb 265.66%
Jan 265.5%
Jan 265.48%
Jan 265.55%
Jan 265.3%
Jan 265.14%
Dec 255.2%
Dec 255.12%
Dec 254.99%
Dec 254.88%
Nov 254.91%
Nov 254.97%
Nov 254.77%
Nov 253.66%
Oct 253.49%
Oct 253.4%
Oct 253.48%
Oct 253.47%
Oct 253.4%
Sep 253.29%
Sep 253.1%
Sep 253.11%
Sep 253.17%
Aug 253.17%
Aug 253.05%
Aug 253.02%
Aug 254.03%
Aug 254.33%
Jul 254.2%
Jul 254.17%
Jul 254.52%
Jul 254.6%
Jun 254.68%
Jun 254.85%
Jun 254.85%
Jun 254.96%
May 255.29%
May 255.1%
May 255.35%
May 256.29%
May 256.16%
Apr 256.59%
Apr 256.83%
Apr 256.87%
Apr 256.5%
Mar 255.87%
Mar 256.04%
Mar 256.75%
Mar 256.36%
Feb 256.9%
Feb 255.88%
Feb 256.21%
Feb 256.71%
Jan 257.06%
Jan 257.3%
Jan 257.76%
Jan 257.78%
Jan 257.5%
Dec 247.17%
Dec 247.03%
Dec 247.03%
Dec 246.72%
Nov 247.42%
Nov 246.89%
Nov 247.19%
Nov 247.04%
Nov 247.27%
Oct 247.03%
Price to Sales
246810med 5.15Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
TME Price to Sales by quarter
PeriodPrice to Sales
Sep 262.54
Sep 262.5
Sep 262.59
Aug 262.73
Aug 262.8
Aug 262.83
Aug 263.05
Jul 263.02
Jul 262.84
Jul 262.93
Jul 262.85
Jul 262.78
Jun 262.7
Jun 262.8
Jun 262.96
Jun 262.91
May 262.96
May 262.84
May 262.73
May 263.01
May 262.98
Apr 263.06
Apr 263.29
Apr 263.06
Apr 263.03
Mar 263.12
Mar 263.33
Mar 264.81
Mar 264.62
Feb 264.92
Feb 265.16
Feb 265.38
Feb 265.57
Jan 265.73
Jan 265.75
Jan 265.68
Jan 265.95
Jan 266.14
Dec 256.07
Dec 256.16
Dec 256.32
Dec 256.46
Nov 256.42
Nov 256.34
Nov 256.61
Nov 257.66
Oct 258.03
Oct 258.24
Oct 258.05
Oct 258.09
Oct 258.24
Sep 258.52
Sep 259.03
Sep 259
Sep 258.83
Aug 258.84
Aug 259.18
Aug 259.27
Aug 258.38
Aug 257.8
Jul 258.04
Jul 258.1
Jul 257.47
Jul 257.35
Jun 257.22
Jun 256.97
Jun 256.97
Jun 256.8
May 256.39
May 256.63
May 256.31
May 255.57
May 255.69
Apr 255.32
Apr 255.05
Apr 255.02
Apr 255.31
Mar 255.88
Mar 255.71
Mar 255.11
Mar 255.43
Feb 255
Feb 255.87
Feb 255.56
Feb 255.15
Jan 254.89
Jan 254.73
Jan 254.45
Jan 254.43
Jan 254.6
Dec 244.82
Dec 244.91
Dec 244.91
Dec 245.14
Nov 244.65
Nov 244.71
Nov 244.51
Nov 244.61
Nov 244.46
Oct 244.61
EV/EBITDA
0102030med 17.01Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
TME EV/EBITDA by quarter
PeriodEV/EBITDA
Sep 264.71
Sep 264.62
Sep 264.82
Aug 264.49
Aug 264.65
Aug 264.7
Aug 265.19
Jul 265.13
Jul 264.74
Jul 264.93
Jul 264.76
Jul 264.6
Jun 264.43
Jun 264.65
Jun 264.98
Jun 264.89
May 264.99
May 264.73
May 264.5
May 265.22
May 265.15
Apr 265.33
Apr 265.84
Apr 265.33
Apr 265.25
Mar 265.47
Mar 265.92
Mar 2612.78
Mar 2612.2
Feb 2613.12
Feb 2613.84
Feb 2614.51
Feb 2615.09
Jan 2615.57
Jan 2615.62
Jan 2615.4
Jan 2616.23
Jan 2616.8
Dec 2516.58
Dec 2516.85
Dec 2517.34
Dec 2517.76
Nov 2517.63
Nov 2517.4
Nov 2518.21
Nov 2521.84
Oct 2522.97
Oct 2523.62
Oct 2523.05
Oct 2523.15
Oct 2523.62
Sep 2524.47
Sep 2526.04
Sep 2525.95
Sep 2525.42
Aug 2525.45
Aug 2526.5
Aug 2526.79
Aug 2525.31
Aug 2523.43
Jul 2524.22
Jul 2524.42
Jul 2522.33
Jul 2521.92
Jun 2521.49
Jun 2520.67
Jun 2520.67
Jun 2520.12
May 2518.75
May 2519.54
May 2518.5
May 2516.54
May 2516.94
Apr 2515.69
Apr 2517.64
Apr 2517.51
Apr 2518.73
Mar 2521.09
Mar 2520.4
Mar 2517.9
Mar 2519.2
Feb 2517.42
Feb 2521.05
Feb 2519.75
Feb 2518.03
Jan 2516.97
Jan 2516.29
Jan 2515.12
Jan 2515.07
Jan 2515.76
Dec 2416.66
Dec 2417.05
Dec 2417.04
Dec 2418
Nov 2415.98
Nov 2418.31
Nov 2417.41
Nov 2417.85
Nov 2417.19
Oct 2417.86
Price/Operating Cashflow
010203040med 14.96Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
TME Price/Operating Cashflow by quarter
PeriodPrice/Operating Cashflow
Sep 267.47
Sep 267.35
Sep 267.61
Aug 268.88
Aug 269.12
Aug 269.19
Aug 269.91
Jul 269.84
Jul 269.25
Jul 269.53
Jul 269.28
Jul 269.03
Jun 268.79
Jun 269.11
Jun 269.61
Jun 269.47
May 269.62
May 269.23
May 268.89
May 269.47
May 269.36
Apr 269.62
Apr 2610.35
Apr 269.63
Apr 269.51
Mar 269.82
Mar 2610.47
Mar 2614.78
Mar 2614.19
Feb 2615.13
Feb 2615.86
Feb 2616.54
Feb 2617.13
Jan 2617.62
Jan 2617.67
Jan 2617.45
Jan 2618.29
Jan 2618.87
Dec 2518.65
Dec 2518.92
Dec 2519.42
Dec 2519.85
Nov 2519.72
Nov 2519.49
Nov 2520.3
Nov 2526.34
Oct 2527.61
Oct 2528.34
Oct 2527.69
Oct 2527.81
Oct 2528.33
Sep 2529.29
Sep 2531.05
Sep 2530.95
Sep 2530.36
Aug 2530.39
Aug 2531.57
Aug 2531.89
Aug 2524.02
Aug 2522.38
Jul 2523.07
Jul 2523.24
Jul 2521.43
Jul 2521.08
Jun 2520.7
Jun 2519.99
Jun 2519.98
Jun 2519.51
May 2518.32
May 2519
May 2518.1
May 2515.4
May 2515.73
Apr 2514.71
Apr 2514.39
Apr 2514.3
Apr 2515.13
Mar 2516.75
Mar 2516.28
Mar 2514.57
Mar 2515.45
Feb 2514.24
Feb 2516.72
Feb 2515.83
Feb 2514.66
Jan 2513.93
Jan 2513.47
Jan 2512.66
Jan 2512.63
Jan 2513.1
Dec 2413.72
Dec 2413.98
Dec 2413.98
Dec 2414.63
Nov 2413.25
Nov 2414.25
Nov 2413.66
Nov 2413.95
Nov 2413.51
Oct 2413.96
Price to Book
1234med 2.13Dec 24Apr 25Jul 25Nov 25Feb 26Jun 26Sep 26
TME Price to Book by quarter
PeriodPrice to Book
Sep 261.03
Sep 261.02
Sep 261.05
Aug 261.15
Aug 261.19
Aug 261.19
Aug 261.29
Jul 261.28
Jul 261.2
Jul 261.24
Jul 261.21
Jul 261.17
Jun 261.14
Jun 261.18
Jun 261.25
Jun 261.23
May 261.25
May 261.2
May 261.16
May 261.16
May 261.15
Apr 261.18
Apr 261.27
Apr 261.18
Apr 261.17
Mar 261.2
Mar 261.28
Mar 261.79
Mar 261.71
Feb 261.83
Feb 261.92
Feb 262
Feb 262.07
Jan 262.13
Jan 262.13
Jan 262.11
Jan 262.21
Jan 262.28
Dec 252.25
Dec 252.29
Dec 252.35
Dec 252.4
Nov 252.38
Nov 252.35
Nov 252.45
Nov 252.68
Oct 252.81
Oct 252.89
Oct 252.82
Oct 252.83
Oct 252.89
Sep 252.99
Sep 253.16
Sep 253.15
Sep 253.09
Aug 253.1
Aug 253.22
Aug 253.25
Aug 253.23
Aug 253.01
Jul 253.1
Jul 253.12
Jul 252.88
Jul 252.83
Jun 252.78
Jun 252.69
Jun 252.69
Jun 252.62
May 252.46
May 252.55
May 252.43
May 252.27
May 252.32
Apr 252.17
Apr 252.16
Apr 252.14
Apr 252.27
Mar 252.51
Mar 252.44
Mar 252.18
Mar 252.32
Feb 252.13
Feb 252.51
Feb 252.37
Feb 252.2
Jan 252.09
Jan 252.02
Jan 251.9
Jan 251.89
Jan 251.96
Dec 242.06
Dec 242.09
Dec 242.09
Dec 242.19
Nov 241.99
Nov 242.05
Nov 241.97
Nov 242.01
Nov 241.94
Oct 242.01
Tencent Music Entertainment Group
TME
Stockpicker

Video analysis: TME

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: TME

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu

gurufocus.com · 13 Sep 2026

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu

Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. [url="]announced[/url] that updated data, including overall survival (OS), from

Tencent Music Entertainment Group Announces Closing of US$1,000 Million Notes Offering

prnewswire.com · 10 Sep 2026

Tencent Music Entertainment Group Announces Closing of US$1,000 Million Notes Offering

SHENZHEN, China, Sept. 10, 2026 /PRNewswire/ -- Tencent Music Entertainment Group ("TME," or the "Company") (NYSE: TME and HKEX: 1698), the leading all-in-one music and audio entertainment platform in China, today announced the closing of its public offering of US$1,000 million aggregate principal amount of senior unsecured notes consisting of US$500 million of 5.050% notes due 2031 and US$500 million of 5.650% notes due 2036.

BIGBANG 2026-2027 WORLD TOUR < XX: COSMOS > IN HONG KONG Officially Announced

gurufocus.com · 8 Sep 2026

BIGBANG 2026-2027 WORLD TOUR < XX: COSMOS > IN HONG KONG Officially Announced

BIGBANG 2026-2027 WORLD TOUR IN HONG KONG Officially Announced PR Newswire HONG KONG, Sept. 8, 2026

Tencent Music Entertainment Group Announces Pricing of US$1,000 Million Notes Offering

prnewswire.com · 3 Sep 2026

Tencent Music Entertainment Group Announces Pricing of US$1,000 Million Notes Offering

SHENZHEN, China, Sept. 3, 2026 /PRNewswire/ -- Tencent Music Entertainment Group ("TME," or the "Company") (NYSE: TME and HKEX: 1698), the leading all-in-one music and audio entertainment platform in China, today announced its public offering of US$1,000 million aggregate principal amount of its senior unsecured notes.

Tencent Music Entertainment Group Announces Notes Offering

prnewswire.com · 1 Sep 2026

Tencent Music Entertainment Group Announces Notes Offering

SHENZHEN, China, Sept. 1, 2026 /PRNewswire/ -- Tencent Music Entertainment Group ("TME," or the "Company") (NYSE: TME and HKEX: 1698), the leading all-in-one music and audio entertainment platform in China, today announced its proposed public offering (the "Proposed Offering") of its senior unsecured notes in one or more tranches, subject to market conditions and other factors.

Tencent Music Entertainment Group Sponsored ADR (NYSE:TME) Receives Average Rating of “Hold” from Brokerages

defenseworld.net · 31 Aug 2026

Tencent Music Entertainment Group Sponsored ADR (NYSE:TME) Receives Average Rating of “Hold” from Brokerages

Shares of Tencent Music Entertainment Group Sponsored ADR (NYSE: TME - Get Free Report) have been given an average rating of "Hold" by the thirteen ratings firms that are presently covering the firm, Marketbeat.com reports. Ten equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the

Comparing NEXON (OTCMKTS:NEXOY) and Tencent Music Entertainment Group (NYSE:TME)

defenseworld.net · 29 Aug 2026

Comparing NEXON (OTCMKTS:NEXOY) and Tencent Music Entertainment Group (NYSE:TME)

NEXON (OTCMKTS:NEXOY - Get Free Report) and Tencent Music Entertainment Group (NYSE: TME - Get Free Report) are both large-cap communication services companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability. Dividends NEXON pays an annual

Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology

gurufocus.com · 25 Aug 2026

Ivonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lanc

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.